No immediate trading catalyst. Monitor the next quarterly earnings call for any strategic or capital allocation shifts under the new CFO. The appointment of a seasoned J&J finance executive is incrementally positive for governance credibility but does not change near-term fundamentals.
Price Chart
Executive Summary
Halozyme appointed Darren Snellgrove as permanent CFO, effective June 8, 2026, replacing interim CFO David Ramsay who will stay on in an advisory role. Snellgrove brings deep biopharma finance experience from 27 years at Johnson & Johnson, most recently as VP of Investor Relations and previously as CFO of J&J's Pharmaceutical sector. This is a routine executive appointment with no material financial impact.
Key Facts
- Darren Snellgrove appointed CFO effective June 8, 2026, replacing interim CFO David Ramsay
- Snellgrove spent 27 years at Johnson & Johnson, most recently as VP of Investor Relations and previously as CFO of J&J's Pharmaceutical sector
- Annual base salary of $670,000 with 50% bonus target, new-hire equity awards totaling $7,200,000 ($3.2M RSUs + $4.0M stock options), and a $350,000 sign-on cash bonus
- Current interim CFO David Ramsay will remain in an advisory role during the transition
Financial Impact
New CFO compensation package includes $670,000 salary, $7.2M equity grant, and $350,000 sign-on bonus — immaterial relative to $7.5B market cap
Risk Factors
- Transition risk if Snellgrove's strategic priorities diverge from the interim CFO's approach
- No change to underlying business fundamentals or revenue outlook
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001159036-26-000053 |
| Document: darrensnellgrovepressrelea.htm | 0001159036-26-000053 |
| Document: 0001159036-26-000053-index-headers.html | 0001159036-26-000053 |
| Document: 0001159036-26-000053-index.html | 0001159036-26-000053 |
| Document: 0001159036-26-000053.txt | 0001159036-26-000053 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 20, 2026 6w ago | Insider Cluster | $106.12 $112.45 | ▲ +5.96% | ▲ +5.96% | $109.25 (+2.94%) |
Jul 9, 2026 12w ago | Insider Cluster | $78.62 $85.76 | ▲ +9.08% | ▲ +6.84% | $109.25 (+38.95%) |
Jul 2, 2026 13w ago | Insider Cluster | $79.45 $83.30 | ▲ +4.85% | ▲ +5.26% | $109.25 (+37.50%) |
Jun 4, 2026 17w ago | Insider Cluster | $71.60 $79.45 | ▲ +10.96% | ▲ +12.34% | $109.25 (+52.58%) |
Apr 30, 2026 22w ago | 8-K | $63.66 $68.18 | ▲ +7.10% | ▲ +2.13% | $109.25 (+71.61%) |
Mar 23, 2026 27w ago | DEFA14A | $62.04 $68.40 | ▲ +10.25% | ▲ +1.35% | $109.25 (+76.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access